In brief, the treatment of uveitis with IFN-γ shows opportunities and challenges, while the drug targeting both Th1 and pathogenic Th17 cells or inducing them to transform into Tregs may be a better choice for treating autoimmune uveitis. The gene discussed is IFNG; the disease is uveitis.